Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00002519

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00002519. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PH I Continuous Infusion Taxol in Combination With Thoracic Radiation Therapy in Untreated Locally Advanced Non-Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with paclitaxel in combination with radiation therapy to the chest in patients with previously untreated stage III non-small cell lung cancer that cannot be surgically removed.

Study identification

NCT ID: NCT00002519
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Enrollment: 6 participants

Conditions and interventions

Conditions

Lung Cancer

Interventions

Drug · Radiation

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 1997 (Type not available)
Primary completion: Jan 2000 (Actual)
Completion: Jan 2000 (Actual)
Last update posted: May 3, 2013

1997 – 2000

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
University of Pennsylvania Cancer Center	Philadelphia	Pennsylvania	19104	—
Sarah Cannon-Minnie Pearl Cancer Center	Nashville	Tennessee	37203	—
Vanderbilt Cancer Center	Nashville	Tennessee	37232-6838	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00002519, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 3, 2013 · Synced Nov 12, 2026